405,576 Shares in Arvinas, Inc. (NASDAQ:ARVN) Bought by Baker BROS. Advisors LP

Baker BROS. Advisors LP acquired a new stake in shares of Arvinas, Inc. (NASDAQ:ARVN) in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 405,576 shares of the company’s stock, valued at approximately $9,989,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the company. Quest Partners LLC acquired a new stake in shares of Arvinas during the 2nd quarter valued at about $42,000. nVerses Capital LLC acquired a new position in Arvinas in the third quarter worth approximately $39,000. Amalgamated Bank raised its position in Arvinas by 29.6% during the second quarter. Amalgamated Bank now owns 2,223 shares of the company’s stock valued at $59,000 after acquiring an additional 508 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its stake in Arvinas by 21.5% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,483 shares of the company’s stock valued at $61,000 after acquiring an additional 440 shares during the last quarter. Finally, Quantbot Technologies LP grew its position in Arvinas by 147.3% in the third quarter. Quantbot Technologies LP now owns 4,367 shares of the company’s stock worth $108,000 after acquiring an additional 2,601 shares in the last quarter. Hedge funds and other institutional investors own 95.19% of the company’s stock.

Arvinas Trading Up 2.8 %

ARVN opened at $26.72 on Monday. The business has a 50 day moving average of $25.68 and a 200-day moving average of $26.74. The stock has a market capitalization of $1.84 billion, a price-to-earnings ratio of -5.72 and a beta of 1.96. Arvinas, Inc. has a 1-year low of $21.17 and a 1-year high of $53.08.

Arvinas (NASDAQ:ARVN) last released its earnings results on Wednesday, October 30th. The company reported ($0.68) EPS for the quarter, beating the consensus estimate of ($0.88) by $0.20. The company had revenue of $102.40 million for the quarter, compared to analyst estimates of $60.56 million. Arvinas’s revenue for the quarter was up 196.0% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($1.18) earnings per share. Equities analysts predict that Arvinas, Inc. will post -3.24 EPS for the current year.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on ARVN shares. Stephens assumed coverage on shares of Arvinas in a report on Monday, November 18th. They set an “overweight” rating and a $55.00 price target on the stock. Oppenheimer cut their target price on Arvinas from $50.00 to $40.00 and set an “outperform” rating on the stock in a report on Thursday, October 31st. Cantor Fitzgerald reiterated an “overweight” rating on shares of Arvinas in a research note on Monday, September 9th. HC Wainwright reissued a “buy” rating and issued a $87.00 price objective on shares of Arvinas in a research note on Thursday, October 31st. Finally, BMO Capital Markets decreased their target price on Arvinas from $90.00 to $88.00 and set an “outperform” rating for the company in a research report on Wednesday, November 20th. One research analyst has rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $61.08.

About Arvinas

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins.